Birhan Demirhan
Research Subjects
Birhan Demirhan has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
- Aysenur Elmali
Department of Radiation Oncology Baskent University Faculty of Medicine Ankara Turkiye
11 shared publications - Cem Onal
Department of Radiation Oncology, Adana Dr. Turgut Noyan Research and Treatment Center, Baskent University Faculty of Medicine, Adana, Turkey
11 shared publications - Ozan Cem Guler
Baskent University Faculty of Medicine, Adana Dr Turgut Noyan Research and Treatment Center, Department of Radiation Oncology, Adana, Turkey
7 shared publications - Melek Yavuz
Department of Radiation Oncology, Başkent University Faculty of Medicine, Ankara, Turkiye
4 shared publications Gurcan Erbay
Department of Radiology, Baskent University Faculty of Medicine Adana Dr Turgut Noyan Research and Treatment Center, Adana, Turkiye
3 shared publicationsOzan Cem Guler
Department of Radiation Oncology Baskent University Faculty of Medicine, Adana Dr Turgut Noyan Research and Treatment Center Adana Turkey
3 shared publications
Latest Publications
- Open Access
- 13 September 2026
- Published by Wiley in The Prostate
- Vol. 86 (16) , 1612-1620
Prognostic Value of MRI‐Derived Apparent Diffusion Coefficient in Intermediate‐Risk Prostate Cancer Treated With Definitive Radiotherapy
Background: Intermediate‐risk prostate cancer (IR‐PCa) is a heterogeneous disease with variable clinical outcomes despite established risk classification. We evaluated whether pretreatment tumor apparent diffusion coefficient (ADC) derived from multiparametric MRI was associated with long‐term outcomes and provided additional prognostic information beyond established clinical risk classification in patients treated with definitive radiotherapy. Methods and Materials: We retrospectively analyzed 238 patients with IR‐PCa treated with definitive radiotherapy. Tumor ADC values were obtained from pre‐treatment diffusion‐weighted MRI. Patients were stratified according to ADC levels and clinical risk subgroups, including favorable and unfavorable intermediate‐risk disease. Survival analyses and Cox regression models were used to assess associations between ADC and clinical outcomes, including biochemical failure and distant metastasis. Results: At a median follow‐up of 10.3 years, 22 patients developed biochemical failure, and 12 developed distant metastases. Lower ADC values (≤ 0.668 × 10 −3 mm 2 /s) were associated with inferior outcomes, with a significant impact on freedom from distant metastasis (FFDM) (HR 3.94, 95% CI 1.14–13.62; p = 0.03). When ADC was combined with clinical risk classification, outcomes differed across the four resulting subgroups for both FFDM ( p = 0.02) and FFBF ( p = 0.02). However, the FIR–low ADC subgroup included only seven patients, and these subgroup findings should be considered exploratory. Conclusions: Lower tumor ADC was associated with an increased risk of distant metastasis and provided exploratory prognostic information beyond established clinical risk classification. Given the limited number of events and the data‐derived cutoff, these findings require external validation before ADC can be used to guide treatment selection.
- 13 September 2026
- Published by Wiley in The Prostate
- Vol. 86 (16) , 1612-1620
Open AccessPrognostic Value of MRI‐Derived Apparent Diffusion Coefficient in Intermediate‐Risk Prostate Cancer Treated With Definitive Radiotherapy
Background: Intermediate‐risk prostate cancer (IR‐PCa) is a heterogeneous disease with variable clinical outcomes despite established risk classification. We evaluated whether pretreatment tumor apparent diffusion coefficient (ADC) derived from multiparametric MRI was associated with long‐term outcomes and provided additional prognostic information beyond established clinical risk classification in patients treated with definitive radiotherapy. Methods and Materials: We retrospectively analyzed 238 patients with IR‐PCa treated with definitive radiotherapy. Tumor ADC values were obtained from pre‐treatment diffusion‐weighted MRI. Patients were stratified according to ADC levels and clinical risk subgroups, including favorable and unfavorable intermediate‐risk disease. Survival analyses and Cox regression models were used to assess associations between ADC and clinical outcomes, including biochemical failure and distant metastasis. Results: At a median follow‐up of 10.3 years, 22 patients developed biochemical failure, and 12 developed distant metastases. Lower ADC values (≤ 0.668 × 10 −3 mm 2 /s) were associated with inferior outcomes, with a significant impact on freedom from distant metastasis (FFDM) (HR 3.94, 95% CI 1.14–13.62; p = 0.03). When ADC was combined with clinical risk classification, outcomes differed across the four resulting subgroups for both FFDM ( p = 0.02) and FFBF ( p = 0.02). However, the FIR–low ADC subgroup included only seven patients, and these subgroup findings should be considered exploratory. Conclusions: Lower tumor ADC was associated with an increased risk of distant metastasis and provided exploratory prognostic information beyond established clinical risk classification. Given the limited number of events and the data‐derived cutoff, these findings require external validation before ADC can be used to guide treatment selection.
- Open Access
- 30 March 2026
- Published by Wiley in The Prostate
- Vol. 86 (8) , 961-969
Impact of Intraprostatic Simultaneous Integrated Boost on Long‐Term Outcomes in Unfavorable Intermediate‐Risk Prostate Cancer Treated With Dose‐Escalated Radiotherapy and Short‐Term Androgen Deprivation Therapy
Background: Unfavorable intermediate‐risk prostate cancer (UIR‐PCa) represents a biologically heterogeneous subgroup with a higher risk of recurrence compared with favorable intermediate‐risk disease. Contemporary management frequently includes dose‐escalated radiotherapy (RT) combined with short‐term androgen deprivation therapy (ADT). Whether additional intraprostatic dose escalation using a simultaneous integrated boost (SIB) provides incremental oncologic benefit in this setting remains uncertain. Methods: We retrospectively analyzed 194 patients with UIR‐PCa treated at three institutions between 2010 and 2023. All patients received image‐guided intensity‐modulated or volumetric modulated arc RT to 78 Gy with short‐term ADT. An MRI‐guided intraprostatic SIB (up to 86 Gy) was delivered in 77 patients (39.7%) at clinician discretion. Primary endpoints were biochemical recurrence‐free survival (bRFS), distant metastasis‐free survival (DMFS), and prostate cancer–specific mortality (PCSM). Multivariable Cox and competing‐risk regression models were used to assess predictors of outcome. Results: After a median follow‐up of 105 months, 8‐year bRFS and DMFS rates for the entire cohort were 93.7% and 95.7%, respectively. Addition of SIB was not associated with improved bRFS (93.5% vs 93.6%, p = 0.36), DMFS (94.6% vs 96.7%, p = 0.15), or PCSM. Percent positive biopsy cores ≥ 50% was the only independent predictor of inferior bRFS on multivariable analysis. Treatment‐related toxicity was low in both groups, with no significant differences in late grade ≥ 2 gastrointestinal or genitourinary toxicity. Conclusions: In patients with UIR‐PCa uniformly treated with dose‐escalated, image‐guided RT and short‐term ADT, long‐term oncologic outcomes were excellent. The addition of an intraprostatic SIB was safe but did not confer measurable improvement in biochemical or distant disease control. These findings support a selective rather than routine use of focal intraprostatic dose escalation in contemporary UIR‐PCa management.
- 30 March 2026
- Published by Wiley in The Prostate
- Vol. 86 (8) , 961-969
Open AccessImpact of Intraprostatic Simultaneous Integrated Boost on Long‐Term Outcomes in Unfavorable Intermediate‐Risk Prostate Cancer Treated With Dose‐Escalated Radiotherapy and Short‐Term Androgen Deprivation Therapy
Background: Unfavorable intermediate‐risk prostate cancer (UIR‐PCa) represents a biologically heterogeneous subgroup with a higher risk of recurrence compared with favorable intermediate‐risk disease. Contemporary management frequently includes dose‐escalated radiotherapy (RT) combined with short‐term androgen deprivation therapy (ADT). Whether additional intraprostatic dose escalation using a simultaneous integrated boost (SIB) provides incremental oncologic benefit in this setting remains uncertain. Methods: We retrospectively analyzed 194 patients with UIR‐PCa treated at three institutions between 2010 and 2023. All patients received image‐guided intensity‐modulated or volumetric modulated arc RT to 78 Gy with short‐term ADT. An MRI‐guided intraprostatic SIB (up to 86 Gy) was delivered in 77 patients (39.7%) at clinician discretion. Primary endpoints were biochemical recurrence‐free survival (bRFS), distant metastasis‐free survival (DMFS), and prostate cancer–specific mortality (PCSM). Multivariable Cox and competing‐risk regression models were used to assess predictors of outcome. Results: After a median follow‐up of 105 months, 8‐year bRFS and DMFS rates for the entire cohort were 93.7% and 95.7%, respectively. Addition of SIB was not associated with improved bRFS (93.5% vs 93.6%, p = 0.36), DMFS (94.6% vs 96.7%, p = 0.15), or PCSM. Percent positive biopsy cores ≥ 50% was the only independent predictor of inferior bRFS on multivariable analysis. Treatment‐related toxicity was low in both groups, with no significant differences in late grade ≥ 2 gastrointestinal or genitourinary toxicity. Conclusions: In patients with UIR‐PCa uniformly treated with dose‐escalated, image‐guided RT and short‐term ADT, long‐term oncologic outcomes were excellent. The addition of an intraprostatic SIB was safe but did not confer measurable improvement in biochemical or distant disease control. These findings support a selective rather than routine use of focal intraprostatic dose escalation in contemporary UIR‐PCa management.
- 26 May 2025
- Published by Wiley in The Prostate
- Vol. 85 (12) , 1155-1156
SBRT Boost in Prostate Cancer: Progress Made, Questions Remain
- 26 May 2025
- Published by Wiley in The Prostate
- Vol. 85 (12) , 1155-1156
SBRT Boost in Prostate Cancer: Progress Made, Questions Remain
- Open Access
- 11 March 2025
- Published by Wiley in The Prostate
- Vol. 85 (8) , 805-813
Propensity Score Matched Analysis of External Beam Radiotherapy With or Without Focal Boost to Intraprostatic Lesions in Prostate Cancer
Background: This study evaluated the impact of radiotherapy (RT) with or without a simultaneous integrated boost (SIB) to intraprostatic lesions on survival, recurrence, and toxicity in localized prostate cancer (PCa). Key prognostic and predictive factors were also analyzed.Materials and Methods: A retrospective analysis included 712 intermediate‐ and high‐risk PCa patients treated with external beam RT at 78 Gy, with or without SIB (up to 86 Gy), between 2010 and 2018. Propensity score matching (PSM) was used to ensure comparability. Outcomes assessed included biochemical disease‐free survival (bDFS), prostate cancer‐specific survival (PCSS), local recurrence (LR), distant metastasis (DM), and treatment‐related toxicities.Results: After PSM, 417 patients were analyzed (208 with SIB, 209 without). Over a median follow‐up of 8.6 years, the SIB group showed higher 8‐year bDFS (93.8% vs. 83.5%; p = 0.006) and lower rates of DM (6.1% vs. 13.0%; p = 0.003) and LR (1.8% vs. 6.9%; p = 0.03). PCSS was similar between groups (95.7% vs. 92.3%; p = 0.38). Advanced T stage and absence of SIB were predictors of worse bDFS, DM, and LR, while higher Gleason score were associated with poorer PCSS and DM in multivariable analysis. There were no significant differences in 8‐year Grade ≥ 2 GU (10.1% vs. 10.5%; p = 0.98) or GI (7.8% vs. 6.5%; p = 0.64) toxicities between the SIB and non‐SIB groups.Conclusions: SIB with external beam RT significantly improves bDFS and reduces LR and DM in intermediate‐ and high‐risk PCa, with no increase in significant toxicities. These findings emphasize the value of dose escalation in achieving better local control and long‐term outcomes while maintaining patient safety.
- 11 March 2025
- Published by Wiley in The Prostate
- Vol. 85 (8) , 805-813
Open AccessPropensity Score Matched Analysis of External Beam Radiotherapy With or Without Focal Boost to Intraprostatic Lesions in Prostate Cancer
Background: This study evaluated the impact of radiotherapy (RT) with or without a simultaneous integrated boost (SIB) to intraprostatic lesions on survival, recurrence, and toxicity in localized prostate cancer (PCa). Key prognostic and predictive factors were also analyzed.Materials and Methods: A retrospective analysis included 712 intermediate‐ and high‐risk PCa patients treated with external beam RT at 78 Gy, with or without SIB (up to 86 Gy), between 2010 and 2018. Propensity score matching (PSM) was used to ensure comparability. Outcomes assessed included biochemical disease‐free survival (bDFS), prostate cancer‐specific survival (PCSS), local recurrence (LR), distant metastasis (DM), and treatment‐related toxicities.Results: After PSM, 417 patients were analyzed (208 with SIB, 209 without). Over a median follow‐up of 8.6 years, the SIB group showed higher 8‐year bDFS (93.8% vs. 83.5%; p = 0.006) and lower rates of DM (6.1% vs. 13.0%; p = 0.003) and LR (1.8% vs. 6.9%; p = 0.03). PCSS was similar between groups (95.7% vs. 92.3%; p = 0.38). Advanced T stage and absence of SIB were predictors of worse bDFS, DM, and LR, while higher Gleason score were associated with poorer PCSS and DM in multivariable analysis. There were no significant differences in 8‐year Grade ≥ 2 GU (10.1% vs. 10.5%; p = 0.98) or GI (7.8% vs. 6.5%; p = 0.64) toxicities between the SIB and non‐SIB groups.Conclusions: SIB with external beam RT significantly improves bDFS and reduces LR and DM in intermediate‐ and high‐risk PCa, with no increase in significant toxicities. These findings emphasize the value of dose escalation in achieving better local control and long‐term outcomes while maintaining patient safety.
- Open Access
- 28 February 2025
- Published by Springer Nature in Strahlentherapie und Onkologie
- Vol. 201 (8) , 828-836
Optimizing treatment for Gleason 10 prostate cancer: radiation dose escalation and 68Ga-PSMA-PET/CT staging
Purpose: This study aimed to investigate the effects of dose escalation through focal boost (FB) to intraprostatic lesions (IPLs) as well as the role of gallium-68 prostate-specific membrane antigen positron-emission tomography (68Ga-PSMA-PET/CT) for staging and treatment planning in patients with Gleason score (GS) 10 prostate cancer (PCa) receiving definitive radiotherapy (RT) and androgen deprivation therapy (ADT). Materials and methods: We retrospectively analyzed data of 92 patients with GS 10 PCa who underwent definitive RT and ADT from March 2010 to October 2022. Freedom from biochemical failure (FFBF), prostate cancer-specific survival (PCSS), distant metastasis-free survival (DMFS), and overall survival (OS) rates were calculated using the Kaplan–Meier method. Survival outcomes were compared between patients staged with 68Ga-PSMA-PET/CT and those staged with conventional imaging modalities as well as between those who received a simultaneous integrated boost (SIB) and those who did not. Results: At a median follow-up time of 73 months, the 5‑year FFBF, PCSS, DMFS, and OS rates were 59.2%, 77.0%, 62.9%, and 67.6%, respectively. Disease progression was observed in 39 patients (42.4%), with most cases manifesting as distant metastasis (DM). A total of 56 patients (60.9%) were staged using 68Ga-PSMA-PET/CT, while 43 patients (46.7%) received FB to IPLs. Patients staged with 68Ga-PSMA-PET/CT had better FFBF and PCSS compared to those staged with conventional imaging. Patients undergoing an SIB had improved PCSS and DMFS. In the multivariable analysis, an ADT duration of 18 months or more was associated with improved FFBF, PCSS, DMFS, and OS. Application of an SIB was an additional independent predictor for improved FFBF, while staging with 68Ga-PSMA-PET/CT was associated with better PCSS. Conclusion: We found that long-term ADT, increasing the radiation dose to primary tumor, and staging with 68Ga-PSMA-PET/CT improved clinical outcomes. Additional research is needed for validation.
- 28 February 2025
- Published by Springer Nature in Strahlentherapie und Onkologie
- Vol. 201 (8) , 828-836
Open AccessOptimizing treatment for Gleason 10 prostate cancer: radiation dose escalation and 68Ga-PSMA-PET/CT staging
Purpose: This study aimed to investigate the effects of dose escalation through focal boost (FB) to intraprostatic lesions (IPLs) as well as the role of gallium-68 prostate-specific membrane antigen positron-emission tomography (68Ga-PSMA-PET/CT) for staging and treatment planning in patients with Gleason score (GS) 10 prostate cancer (PCa) receiving definitive radiotherapy (RT) and androgen deprivation therapy (ADT). Materials and methods: We retrospectively analyzed data of 92 patients with GS 10 PCa who underwent definitive RT and ADT from March 2010 to October 2022. Freedom from biochemical failure (FFBF), prostate cancer-specific survival (PCSS), distant metastasis-free survival (DMFS), and overall survival (OS) rates were calculated using the Kaplan–Meier method. Survival outcomes were compared between patients staged with 68Ga-PSMA-PET/CT and those staged with conventional imaging modalities as well as between those who received a simultaneous integrated boost (SIB) and those who did not. Results: At a median follow-up time of 73 months, the 5‑year FFBF, PCSS, DMFS, and OS rates were 59.2%, 77.0%, 62.9%, and 67.6%, respectively. Disease progression was observed in 39 patients (42.4%), with most cases manifesting as distant metastasis (DM). A total of 56 patients (60.9%) were staged using 68Ga-PSMA-PET/CT, while 43 patients (46.7%) received FB to IPLs. Patients staged with 68Ga-PSMA-PET/CT had better FFBF and PCSS compared to those staged with conventional imaging. Patients undergoing an SIB had improved PCSS and DMFS. In the multivariable analysis, an ADT duration of 18 months or more was associated with improved FFBF, PCSS, DMFS, and OS. Application of an SIB was an additional independent predictor for improved FFBF, while staging with 68Ga-PSMA-PET/CT was associated with better PCSS. Conclusion: We found that long-term ADT, increasing the radiation dose to primary tumor, and staging with 68Ga-PSMA-PET/CT improved clinical outcomes. Additional research is needed for validation.
- 1 December 2024
- Published by Wiley in The Prostate
- Vol. 85 (4) , 344-353
Evaluating the Prognostic Impact of Apparent Diffusion Coefficient in Definitive Radiotherapy for Gleason Score 7 Prostate Cancer Patients
Background: To investigate the utility of diffusion‐weighted magnetic resonance imaging (DW‐MRI) in evaluating Gleason score (GS) 7 tumors before definitive radiotherapy (RT) and to explore its association with clinicopathological factors and treatment outcomes.Materials and Methods: Clinical data of 266 prostate cancer (PCa) patients with biopsy‐confirmed GS 7 who underwent RT were retrospectively analyzed. Pretreatment DW‐MRI was utilized to measure apparent diffusion coefficient (ADC) values of primary tumors. Treatment outcomes, including biochemical disease‐free survival (bDFS) and prostate cancer‐specific survival (PCSS), were assessed. Statistical analyses were conducted to determine the correlation between tumor ADC values, clinicopathological factors, and treatment outcomes.Results: Tumors with a GS of 3 + 4 had significantly higher ADC values than those with a GS of 4 + 3 (0.746 ± 0.150 vs. 0.702 ± 0.157 × 10−³ mm²/s; p < 0.001). Median follow‐up time was 8.6 years, and the 7‐year rates for bDFS and PCSS were 89.1% and 95.3%, respectively. Lower tumor ADC values were significantly correlated with higher GS and increased risk of disease progression. A primary tumor ADC cutoff value of 0.682 × 10−³ mm²/s was identified for predicting disease progression. Patients with higher ADC values exhibited significantly better 7‐year bDFS rates (92.8% vs. 83.2%; p = 0.02). However, GS 4 + 3 tumors independently predicted poorer bDFS and PCSS outcomes. In the multivariable analysis, only GS 4 + 3 tumor was predictive for worse bDFS and PCSS.Conclusions: Tumor ADC values are a reliable biomarker for differentiating between GS 3 + 4 and 4 + 3 tumors in the GS 7 category. Tumors exhibiting lower ADC values have been associated to higher risk factors and an increased likelihood of disease progression, particularly in GS 3 + 4 tumors where GS upgrading could happen.
- 1 December 2024
- Published by Wiley in The Prostate
- Vol. 85 (4) , 344-353
Evaluating the Prognostic Impact of Apparent Diffusion Coefficient in Definitive Radiotherapy for Gleason Score 7 Prostate Cancer Patients
Background: To investigate the utility of diffusion‐weighted magnetic resonance imaging (DW‐MRI) in evaluating Gleason score (GS) 7 tumors before definitive radiotherapy (RT) and to explore its association with clinicopathological factors and treatment outcomes.Materials and Methods: Clinical data of 266 prostate cancer (PCa) patients with biopsy‐confirmed GS 7 who underwent RT were retrospectively analyzed. Pretreatment DW‐MRI was utilized to measure apparent diffusion coefficient (ADC) values of primary tumors. Treatment outcomes, including biochemical disease‐free survival (bDFS) and prostate cancer‐specific survival (PCSS), were assessed. Statistical analyses were conducted to determine the correlation between tumor ADC values, clinicopathological factors, and treatment outcomes.Results: Tumors with a GS of 3 + 4 had significantly higher ADC values than those with a GS of 4 + 3 (0.746 ± 0.150 vs. 0.702 ± 0.157 × 10−³ mm²/s; p < 0.001). Median follow‐up time was 8.6 years, and the 7‐year rates for bDFS and PCSS were 89.1% and 95.3%, respectively. Lower tumor ADC values were significantly correlated with higher GS and increased risk of disease progression. A primary tumor ADC cutoff value of 0.682 × 10−³ mm²/s was identified for predicting disease progression. Patients with higher ADC values exhibited significantly better 7‐year bDFS rates (92.8% vs. 83.2%; p = 0.02). However, GS 4 + 3 tumors independently predicted poorer bDFS and PCSS outcomes. In the multivariable analysis, only GS 4 + 3 tumor was predictive for worse bDFS and PCSS.Conclusions: Tumor ADC values are a reliable biomarker for differentiating between GS 3 + 4 and 4 + 3 tumors in the GS 7 category. Tumors exhibiting lower ADC values have been associated to higher risk factors and an increased likelihood of disease progression, particularly in GS 3 + 4 tumors where GS upgrading could happen.
- Open Access
- 5 November 2024
- Published by Medical Journals Sweden AB in Acta Oncologica
- Vol. 63, 858-866
The impact of age on clinicopathological features and treatment results in patients with localised prostate cancer receiving definitive radiotherapy
Background: This study assessed the biochemical disease-free survival (bDFS), prostate cancer-specific survival (PCSS), overall survival (OS), and side effects in patients aged < 70 and ≥ 70 years following definitive radiotherapy (RT). It also analysed the correlation between age at diagnosis and clinicopathological characteristics of prostate cancer (PCa). Methods: The prognostic factors for bDFS, PCSS, and OS were determined through univariable and multivariable analyses. Two age groups were also compared in terms of acute and late grade ≥ 2 genitourinary (GU) and gastrointestinal (GI) toxicities, the predictors of which were determined through logistic regression analysis. Results: Of the 1,328 patients, 715 (53.8%) and 613 (46.2%) were aged < 70 and ≥ 70 years, respectively. Median follow-up time was 84.5 months. No significant differences in the 7-year bDFS (86.3% vs. 86.8%) and PCSS rates (92.9% vs. 93.3%) were found between the ≥ 70 and < 70 age groups. The multivariable analysis showed that advanced clinical T stage, high International Society of Urological Pathology (ISUP) grade, and high-risk disease independently predicted poor bDFS and PCSS. Metastatic lymph nodes were another bDFS prognostic factor. The multivariable analysis identified age ≥ 70 years, cardiac events at diagnosis, advanced stage, higher ISUP grade, and non-use of simultaneous integrated boost technique as negative factors for OS. Additionally, diabetes and transurethral resection of the prostate (TUR-P) independently predict late-grade ≥ 2 GU toxicity. Interpretation: Definitive RT is a safe and effective treatment for patients with localised PCa no matter their age. Although patients over 70 years have higher risk factors and comorbidities, their bDFS, PCSS, and toxicities were comparable to those of patients aged < 70 years.
- 5 November 2024
- Published by Medical Journals Sweden AB in Acta Oncologica
- Vol. 63, 858-866
Open AccessThe impact of age on clinicopathological features and treatment results in patients with localised prostate cancer receiving definitive radiotherapy
Background: This study assessed the biochemical disease-free survival (bDFS), prostate cancer-specific survival (PCSS), overall survival (OS), and side effects in patients aged < 70 and ≥ 70 years following definitive radiotherapy (RT). It also analysed the correlation between age at diagnosis and clinicopathological characteristics of prostate cancer (PCa). Methods: The prognostic factors for bDFS, PCSS, and OS were determined through univariable and multivariable analyses. Two age groups were also compared in terms of acute and late grade ≥ 2 genitourinary (GU) and gastrointestinal (GI) toxicities, the predictors of which were determined through logistic regression analysis. Results: Of the 1,328 patients, 715 (53.8%) and 613 (46.2%) were aged < 70 and ≥ 70 years, respectively. Median follow-up time was 84.5 months. No significant differences in the 7-year bDFS (86.3% vs. 86.8%) and PCSS rates (92.9% vs. 93.3%) were found between the ≥ 70 and < 70 age groups. The multivariable analysis showed that advanced clinical T stage, high International Society of Urological Pathology (ISUP) grade, and high-risk disease independently predicted poor bDFS and PCSS. Metastatic lymph nodes were another bDFS prognostic factor. The multivariable analysis identified age ≥ 70 years, cardiac events at diagnosis, advanced stage, higher ISUP grade, and non-use of simultaneous integrated boost technique as negative factors for OS. Additionally, diabetes and transurethral resection of the prostate (TUR-P) independently predict late-grade ≥ 2 GU toxicity. Interpretation: Definitive RT is a safe and effective treatment for patients with localised PCa no matter their age. Although patients over 70 years have higher risk factors and comorbidities, their bDFS, PCSS, and toxicities were comparable to those of patients aged < 70 years.
- 21 August 2024
- Published by Wiley in The Prostate
- Vol. 84 (15) , 1413-1414
Nomograms for detecting lymph node metastasis detected with surgery—Can you name any birds other than crow?
- 21 August 2024
- Published by Wiley in The Prostate
- Vol. 84 (15) , 1413-1414
Nomograms for detecting lymph node metastasis detected with surgery—Can you name any birds other than crow?